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Abstract
Breast conservation therapy (BCT) is the procedure of choice for the management of the early stage breast cancer.
However, its utilization has not been maximized because of logistics issues associated with the protracted
treatment involved with the radiation treatment. Accelerated Partial Breast Irradiation (APBI) is an approach that
treats only the lumpectomy bed plus a 1-2 cm margin, rather than the whole breast. Hence because of the small
volume of irradiation a higher dose can be delivered in a shorter period of time. There has been growing interest
for APBI and various approaches have been developed under phase I-III clinical studies; these include multicatheter
interstitial brachytherapy, balloon catheter brachytherapy, conformal external beam radiation therapy and intra-
operative radiation therapy (IORT). Balloon-based brachytherapy approaches include Mammosite, Axxent electronic
brachytherapy and Contura, Hybrid brachytherapy devices include SAVI and ClearPath. This paper reviews the dif-
ferent techniques, identifying the weaknesses and strength of each approach and proposes a direction for future
research and development. It is evident that APBI will play a role in the management of a selected group of early
breast cancer. However, the relative role of the different techniques is yet to be clearly identified.
Introduction
Breast cancer is a worldwide problem, accounting for
10.4% of all cancer incidence among women, making it
the second most common type of non-skin cancer (after
lung cancer) and the fifth most common cause of cancer
death. In the USA, breast cancer has the highest inci-
dence among all cancer types in females with one in
every eight to ten women being affected during her life-
time [1]; it is estimated that 192,370 women will be
diagnosed with, and 40,170 women will die of, cancer of
the breast in 2009 [2-4].
Breast cancer is the most common cancer in the UK
among women although it is rare in men. In 2006 there
were 45,822 new cases of breast cancer diagnosed in the
UK: 45,508 (over 99%) in women and 314 (less than 1%)
in men. Breast cancer is by far the commonest cancer in
women in the UK accounting for 31% of all cases. The
next most common cancer in women is lung cancer,
with 16,647 cases (11% of total) in 2006. So nearly, a
third of all new cancers in women are breast cancers. It
has been estimated that the lifetime risk of developing
breast cancer is 1 in 1,014 for men and 1 in 9 for
women in the UK. These were calculated using inci-
dence and mortality data for 2001-2005 [5].
Early stage breast cancer is defined as stage II or less;
on the basis of the lack of lymph node, metastasis and
clinical lesion size of 2 cm or less [6]. The ‘surveillance,
epidemiology and end results’ (SEER) program reported
that in 2006, 60% of diagnosed breast cancers are early
stage [2,3]. Similarly in Japan, the fraction of early stage
breast cancer was reported to be 40.6% in 1996 [6].
With the increasing use of breast cancer screening by
mammography, more and more patients will have their
breast cancer diagnosed at the early stage. Hence, there
is a need for proper clinical management of early stage
breast cancer is required. Most women who are newly
diagnosed with early-stage breast cancer have a choice
of: breast-conserving surgery (such as lumpectomy), a
mastectomy (also called a modified radical mastectomy),
radiation therapy and systemic treatments.
Rationale for Breast Conservation
Breast conservation therapy (BCT) is the procedure of
choice for the management of the early stage breast can-
cer. BCT consists of resection of the primary breast
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local excision) followed by whole breast irradiation
(WBI). A total dose of 45-50 Gy is delivered to the
entire breast over 5 to 6 weeks (1.8 to 2 Gy per frac-
tion). In most patients, a boost dose of 10-16 Gy to the
tumor bed is added. The establishment of BCT as the
standard of care resulted from many years of prospec-
tive studies such as the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B-06 studies [7-9].
These studies found equivalent survival and local con-
trol rates among women treated with BCT compared to
those treated with mastectomy.
The value of radiation therapy as a breast conservation
component has been further validated by studies com-
paring lumpectomy alone to lumpectomy and radiation
therapy. These studies demonstrate a threefold reduc-
tion in recurrence with the use of radiation therapy fol-
lowing breast conserving surgery [7,10-13]. For patients
with ductal carcinoma in situ (DCIS), randomized stu-
dies comparing lumpectomy alone to lumpectomy plus
radiation therapy, conducted by the NSABP and
European organization for research and treatment of
cancer (EORTC) found a 55% and 47% reduction in the
ipsilateral breast cancer events respectively, with the
addition of radiation therapy [13,14]. These and other
studies have been recently pooled-analysed by Clarke et
al. [11] and Vinh-Hung et al. [12]. Vinh-Hung’sa n a l y s i s
found that the relative risk of ipsilateral breast tumor
recurrence after breast-conserving surgery, comparing
patients treated with or without radiation therapy, was
3.00 (95% confidence interval [CI] = 2.65 to 3.40).
Further, the relative risk of mortality was 1.086 (95% CI
= 1.003 to 1.175), corresponding to an estimated 8.6%
(95% CI = 0.3% to 17.5%) relative excess mortality if
radiation therapy was omitted. BCT is well tolerated
with minimal long-term complications, favorable cos-
metic outcome and reduced psychological trauma [7,9].
Radiation therapy therefore is an essential component of
BCT. It not only decreases local recurrence but
improves overall survival [11,12]. Because of these excel-
lent results and the better cosmetic outcome, the United
States National Institute of Health released a consensus
statement, recommending breast conserving treatment
as the preferable option for women with early-stage
breast cancer [15].
Rationale for Accelerated Partial Breast
Irradiation (APBI)
Despite the advantages of BCT, its utilization remains a
problem [16]. It has been reported that many women
who are candidates for BCT do not receive it, only 10%
to 80% of patients actually receive it [17-19]. In addition
15% to 30% of patients who undergo lumpectomy do
not receive radiation therapy [20-22]. Similarly in Japan
radiation therapy is performed in approximately 70% of
patients following breast conservation surgery [23]. The
under utilization of BCT has been associated with the
fact that some women cannot, or will not, commit to
the usual 6- 7 week course of adjunct conventional
radiation therapy that is part of the BCT package [24].
It has been further hypothesized that convenience,
access, cost and other logistical issues are major contri-
buting factors. Other logistical issues include: distance
from the radiation therapy facility, lack of transporta-
tion, lack of social support structure and poor ambula-
tory status of the patient [18,25,26]. Other reasons that
may steer women away from BCT that have been identi-
fied include physician bias, patient age and fear of radia-
tion treatments [22]. There has been a desire therefore
to identify a subset of women who may not benefit
from the addition of radiation therapy after lumpectomy
for early stage breast cancer; however, no such subset of
women has been identified [27].
Another criticism of BCT relates to consumption of
resources; while radiation therapy facilities in the USA
have largely kept up with demand for post-lumpectomy
radiation therapy, breast irradiation may constitute
25%-30% of patient visits and can stress a health-care
delivery system. However, nota l lc o u n t r i e sh a v es u c h
adequate resources. For example Palacios Eito et al. [28]
reported that the number of external irradiation units
available in Spain in 2004 (177) was clearly lower than
the number desirable (266-316). There is significant
shortage of radiation therapy equipment in most of Asia
and pacific regions [29], Latin America [30], Africa [31]
and Eastern Europe [32]. In Africa, the actual supply of
megavoltage radiation therapy machines (cobalt or linear
accelerator) was only 155 in 2002, 18% of the estimated
need [31]. In 12 Asia-Pacific countries with available
data, 1147 megavoltage machines were available for
an estimated demand of nearly 4000 megavoltage
machines [32].
The question that arises therefore is ‘can similar rates
of local control be achieved with radiation therapy deliv-
ered only to the area at highest risk for recurrence?’ If
so, radiation could be delivered in a significantly shor-
tened period, thereby potentially making the BCT
option available and attractive to more women. This is
the concept of accelerated partial breast irradiation
(APBI) [26,33,34].
The stronger case for APBI has come from both retro-
spective and prospective studies; reporting that 44% to
86% of local recurrence occurs close to the tumor bed
[10,35-37]. Ipsilateral breast recurrences in areas other
than the tumor bed occurred rarely in 3% to 4% of the
cases [34]. An update of the NSABP B-06 trial also con-
firmed this pattern of local recurrence, with 75% of
recurrences at, or near, the lumpectomy site with other
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recurrence of contra-lateral second primary breast can-
cer [38]. Based upon this evidence, BCT, with whole
breast irradiation has been criticized as an over-
treatment. Whole breast treatments incorporate the
entire breast (including the surgical cavity), overlying
skin, lower axilla and even small portions of the heart
and lung in the treatment fields; this may introduce
avoidable toxicity [39] whereas partial breast irradiation
spares more normal tissue.
An additional theoreticala d v a n t a g eo fA P B Ii sa
decreased dose to normal tissue. With a smaller target
volume, it may be expected that adjacent organs such as
the heart and lungs will receive less radiation. Radia-
tion-induced lung injury after treatment for breast can-
cer, such as pneumonitis, lung fibrosis and pulmonary
function test changes, are well documented in the litera-
ture [40,41]. An increase in lung cancer incidence and
mortality after irradiation for breast cancer has also
been reported in large studies [42-45]. It worth noting
that the increase risk of long-term cardiac-related mor-
tality after BCT may not be significant with modern
breast radiation therapy.
A number of pathology studies have also researched
local breast recurrence [46,47]. In the study by Holland
et al., mastectomy specimens from more than 300
women diagnosed with invasive breast carcinoma, who
fulfilled the criteria for breast conserving therapy, were
systematically investigated [47]. They found that of the
282 invasive cancers, 105 (37%) showed no tumor foci
in the mastectomy specimen around the reference mass.
In 56 cases (20%) tumor foci were present within 2 cm,
and in 121 cases (43%) the tumor was found more than
2 cm from the reference tumor [47]. This study justified
the concept that whole-breast treatment either with sur-
gery or radiation therapy is necessary to achieve local
control. Supporters of APBI argue that this study was
flawed in its patient selection and that the quality of
mammography used at the time may have missed radio-
g r a p h i ce v i d e n c eo fm u l t i centric disease that would
today be detected [48]. Contrary to Holland’s data,
recent studies from women considered appropriate for
breast-conservation therapy reveal that the microscopic
extension of malignant cells is unlikely to be beyond
1 cm [49-51].
Accelerated Partial Breast Irradiation (APBI)
Techniques
APBI is an approach that treats only the lumpectomy
bed plus a 1-2 cm margin, rather than the whole breast.
By increasing the radiation fraction size and decreasing
the target volume, this technique allows the treatment
to be accomplished in a shorter period. APBI is gener-
ally defined as radiation therapy that uses daily fraction
doses greater than 2 Gy delivered in less than 5 weeks.
There are a number of approaches now available for the
implementation of APBI, these include: multi-catheter
interstitial brachytherapy, balloon catheter brachyther-
apy, 3D-CRT (conformal radiation therapy) and intra-
operative radiation therapy (IORT). Each of these tech-
niques is vastly different from one another in terms of
degree of invasiveness, radiation delivery, operator profi-
ciency, acceptance between radiation oncologist and
length of treatment. It is important to review the basic
principles of radiobiology, as well as critical aspects of
patient selection, surgical endpoints and radiotherapy
treatment planning. This paper reviews the different
techniques, identifying the weaknesses and strength of
each approach and proposes a direction for future
research and development.
Multi-catheter Interstitial Brachytherapy (MIB) Treatment
Technique
Multi-catheter interstitial brachytherapy is the APBI
technique that has been utilized the longest and has the
most extensive follow-up [24,33,52]. This technique was
initially developed to provide boost radiation after whole
breast radiation therapy. Flexible after-loading catheters
are placed through the breast tissues surrounding the
lumpectomy. The catheters are inserted at 1 to 1.5 cm
intervals in several planes; firstly to ensure adequate
coverage of the lumpectomy cavity plus margins (Figure
1 ) ,a n ds e c o n d l y ,t oa v o i dh o t and cold spots. The pro-
cedure routinely requires between 14 to 20 catheters to
assure proper dose coverage; the exact number being
determined by the size and shape of the target, deter-
mined using established brachytherapy dosimetric guide-
lines [53,54].
Multiple catheters are placed in the breast using a
free-hand or template-guided approach. The configura-
tion of the catheters and their relation to the tumor tar-
get volume are crucial for effective treatment. Catheter
insertion requires a high level of experience to produce
an implant of excellent quality. The incorporation com-
puted tomography (CT) based 3D planning and image-
guidance has made a significant impact on the quality of
the implants [55]. Determination of optimal catheter
configuration prior to the procedure (virtual planning)
would reduce the dependence of implant quality on the
expertise of the physician [56].
In MIB either low dose rate (LDR) or high dose rate
(HDR) brachytherapy may be used. With LDR, sources
of Ir-192 sources are implanted for approximately 2 to 5
days while the patient is admitted as an inpatient. HDR
however is an outpatient procedure, fractionated over
the course of a week, with each treatment varying
between seconds to minutes. The proposed dose of 34
Gy in 10 fractions BID (twice daily) for HDR was based
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this schema to 45 Gy in 4.5 days of the LDR regimen
used in early APBI trials [57].
The majority of APBI patients treated with the long-
est follow-up have been treated with multi-catheter
interstitial brachytherapy. A systematic review of these
experiences have recently been presented by Offersen
et al. [52]. Polgar et al. [58] and Antonucci et al. [59]
have recently reported 12 year and 10 year follow-up
respectively. In the study of Antonucci et al., eight
ipsilateral breast tumor recurrences (IBTRs) were
observed in patients treated with MIB resulting in a 10
years cumulative incidence of 5% (95% confidence
interval [CI] 1.5-8.5%). The rate of incidence for WBI
was 4% (95% CI: 1.3-6.7%), which not statistically sig-
nificantly different from MIB treated patients. Table 1
presents some of the reported MIB studies with more
than 5 years follow up.
Balloon-Based Brachytherapy Devices
The balloon based brachytherapy include Mammosite,
Axxent electronic brachytherapy, and Contura.
Figure 1 Diagrammatic illustration of multi-catheter interstitial brachytherapy.
Table 1 Results of recent clinical experience with Interstitial brachytherapy with more than 5 years follow up
Author No of
cases
Follow up interval
(years)
Dose rate/pt
no
Scheme Total dose
(Gy)
5-year LR
(%)
Good/Excellent
cosmesis
Strnad et al.[60] 274 5.25 PDR/HDR PDR = 0.6 Gy/hr
HDR = 4 Gy x8
PDR = 50 Gy
HDR = 32 Gy
2.9% 90%
Antonucci et al. [59] 199 9.6 LDR/HDR LDR 0.52 Gy/h × 96
hours
HDR = 4 Gy x8
HDR = 3.4 Gyx10
LDR = 50 Gy
HDR = 32 Gy
HDR = 34 Gy
5% 99%
Johansson et al.[61] 50 7.2 PDR 50Gy/5 50 4% 56%
Arthur et al.[62] 99 7 LDR/HDR LDR = 3.5 -5 days
HDR = 3.4 × 10
45 Gy (LDR)
34 Gy (HDR
4% n/a
Polgar et al.[63] 128 6.8 HDR 5.2 × 7 36.4 Gy 4.7% 77%
King et al [64] 51 6.25 LDR/HDR LDR = 4 days
4 Gyx8
45 Gy (LDR)
32 Gy (HDR)
3.9% 75%
Otto et al. [65] 274 5.25 PDR/HDR PDR 5 days, 0.6 Gy/
hr
HDR = 4 Gyx8
49.8 Gy (PDR)
32 Gy (HDR)
2.9% 92%
Polgar et al.[58] 45 11.1 HDR 4.33 × 7
5.2 × 7
30.3 Gy
36.4 Gy
4.4% 78%
LR = local recurrence, HDR = high dose rate, LDR = low dose rate, PDR = pulsed dose rate, n/a = data not available
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Although MIB has had very encouraging results, the
technical challenges limit its widespread application.
The MammoSite® brachytherapy (MSB) system (Hologic,
Marlborough, MA) applicator was developed to be more
reproducible, easily applied and better tolerated. The
mammosite catheter consists of a silicone balloon con-
nected to a 15 cm double-lumen catheter (Figure 2) that
is 6 mm in diameter. The catheter has both a small
inflation channel and a channel for the passage of an Ir-
192 high dose rate (HDR) brachytherapy source. The
source channel runs centrally through the length of the
balloon. The balloon is inflated with saline solution
mixed with a small amount of contrast material to aid
visualization. The balloon is inflated to a size that would
completely fill the lumpectomy cavity and ensures con-
formance of the tissue to the balloon. An Ir-192 radio-
active source, connected to a computer-controlled HDR
remote after-loader, is inserted through the catheter into
the balloon to deliver the prescription radiation dose
[66,67].
The MammoSite applicator can be placed into the
lumpectomy cavity at the time of surgery or in a sepa-
rate procedure after surgery. In the latter case, the appli-
cator can be inserted under ultrasound guidance either
through the lumpectomy scar or via small separate inci-
sion. Following placement, a computed tomography
(CT) scan is performed to assess the quality of the
implant and for use in radiation planning. Implant
quality is determined by examination of three para-
meters: balloon conformance to the lumpectomy cavity,
distance from the surface of the balloon to the skin sur-
face, and the symmetry of the balloon in relationship to
the central catheter. Treatment planning parameters are:
the diameter of the inflated balloon, the planning target
volume, and the dose distribution [66-68]. While a mini-
mum balloon-to-skin distance of 5 mm is required, a
threshold of at least 7 mm is strongly recommended
[69,70]. A longer skin distance is associated with greater
improvement in cosmesis [71]. Conformance of the bal-
loon to the lumpectomy cavity is assessed by quantifying
the volume of the planning target volume (PTV) that is
filled by air or seroma fluid. Adequate conformance is
considered to have been achieved when less than 10% of
the PTV is composed of fluid or air. A symmetric
implant in relation to the source channel is also essen-
tial for adequate dosimetry. A non-symmetrical implant
can result in dose inhomogeneity in the surrounding tis-
sues since the MSB device contains a single, central
source channel that does not allow for shaping of the
radiation isodose curves in the direction perpendicular
to the central channel [67]. The MSB may not be suita-
ble in patients with small breast or for tumors located
in the upper-inner quadrant because of the requirement
for skin-to-cavity distances. Recently, Hologic has intro-
duced a MammoSite Multi-lumen (4 lumen) device with
the potential to eliminate some of the drawbacks of the
single lumen device (see figure 3)
Figure 2 The MammoSite Balloon applicator (courtesy of Hologic, Marlborough).
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34 Gy over 10 fractions (3.4 Gy per fraction, twice daily
(BID)). The prescription point is 1 cm from the balloon
surface with a minimum of 6 hours between fractions
on the same day.
T h eM S Bw a sa p p r o v e db yt h eU S Af o o da n dd r u g
administration (FDA) in May of 2002 and September
2009, the multi-lumen device was also approved. Bensa-
leh et al [68] and Shah and Wazer [72] have recently
reviewed the MSB system. There are limited published
data regarding the long-term tumor control and cosm-
esis associated with MSB. However, the results thus far
a r ep r o m i s i n g .S o m eo ft h es t u d i e sw i t hm o r et h a n1 2
months follow up are presented in Table 2, with the
longest follow up published by Benitez et al. [73]. In this
study, 43 patients were treated with MSB and had a
median follow up of 65 months. So far, no loco-regional
recurrences have been identified, with cosmetic out-
comes of good to excellent achieved in 81.3% of the
patients. Toxicities were significantly less frequent in
patients with skin spacing of greater than 7 mm. The
American Society of Breast Surgeon (ASBS) [71] registry
trial recently reported 1440 patients treated, with a med-
ian follow up of 30.1 months. There have been 23 cases
(1.6%) of ipsilateral breast tumor recurrence for a two-
year actuarial rate of 1.04%. The cosmetic outcome of
good to excellent was 95% at 12 months. For a subset of
patients (n = 194) with DCIS in the ASBS registry, 6
patients (3.1%) had an ipsilateral breast recurrence, with
1 (0.5%) experiencing recurrence in the breast and axilla,
for a 5-year actuarial local recurrence rate of 3.39% [74].
The acute and late-term toxicity profiles of MSB have
been acceptable. Cosmetic outcome is improved by
proper patient selection and infection prevention [70].
2. Axxent Electronic Brachytherapy
Since the MSB has shown promising results, other
forms of balloon-based brachytherapy have been devel-
oped. The novel Axxent electronic brachytherapy (eB)
system (Xoft, Fremont, CA) is a modified form of bal-
loon-based brachytherapy [67,80] (Figures 4, 5, 6). It is
similar to the MammoSite system, consisting of a bal-
loon catheter that is inserted into the lumpectomy cavity
by means of a percutaneous approach. The catheter
similarly has a central lumen through which the source
is inserted. A second port enables inflation of the bal-
loon with saline and a third port may be attached for
drainage of seroma fluid or air surrounding the lum-
pectomy cavity. The wall of the balloon is covered in
radiolucent material that is visible on a plain x-ray film
or CT scan: addition of radiographic contrast is not
therefore required. The Axxent electronic brachytherapy
system is novel in that it uses an electronic 50 kilo-vol-
tage x-ray source rather then an iridium-192 (
192Ir)
Figure 3 The MammoSite Multilumen System (courtesy of Hologic, Marlborough).
Table 2 Results of some of the recent clinical experience
with Mammosite Brachytherapy System with more than a
year follow up
Author No of
cases
Median follow up
interval (months)
IBF Good/
Excellent
cosmesis
Benitez et al.[73] 43 65 0% 81.3%
Niehoff et al [69] 11 20 0% n/a
Patel et al.[75] 26 48.5 0% n/a
Vicini et al.[71] 1440 30 1.6% 95%
Chen et al.[76] 70 26.1 5.7% n/a
Belkacemi et al. [77] 25 13 0% 84%
Voth et al.[78] 55 24 3.6% n/a
Dragun et al. [70] 90 24 2.2% 90%
Vicini et al.[79] 1440 60 2.6% 90.6%
Jeruss et al. [74] 194
$ 54.4 3.1% 92%
n/a data not available, IBF = ipsilateral breast failure, $ these are ductal
carcinoma in situ (DCIS) patients recruited in the American Society of Breast
Surgeons APBI registry trial.
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o fam i n i a t u r ex - r a yt u b et h a ti si n s e r t e di n t ot h eb a l -
loon catheter and delivers the radiation therapy to the
patient. The eB controller is a portable unit, consisting
of a digital touch-screen for the Physician and Physicist
to input treatment data and monitor treatment progress
[67].
This approach implies that a specifically shielded
r a d i a t i o nr o o mo ra nH D Ra f t e r l o a d e ru n i ta r en o t
required, both of which are needed for treatment with
brachytherapy using Ir-192. The elimination of these
requirements potentially open-up this APBI approach to
a wider usage, particularly for patients who do not live
in close proximity to a radiation center with a HDR
Figure 4 Axxent electronic brachytherapy, controller front view (courtesy of Xoft).
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for treatment and the eB device is very portable, the
number of setting in which the device can be used
increases. It has also been suggested to use the device
for intra-operative radiation therapy [81] and 11 patients
have successfully had IORT using the eB device [82]. eB
received FDA clearance for the treatment of breast can-
cer in January of 2006.
One inherent problem with MSB techniques is the
high skin dose when the excision cavity is near the skin
surface; that can result in late effect skin toxicity. The
Axxent source model S7500 has pronounced anisotropy
resulting in decreased dose at the proximal portion of
the balloon [83]; this can be used as an advantage to
optimize skin dose, particularly, if the cavity to skin dis-
tance is small. This anisotropy can also be accounted
Figure 5 Axxent electronic brachytherapy, HDR X-ray source (courtesy of Xoft).
Figure 6 Axxent electronic brachytherapy, balloon applicator (courtesy of Xoft).
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face along the proximal end of the catheter [67].
Being a relatively new device, there is a dearth in clini-
cal experience and hence there are no clear recommen-
dations on clinical use, for example, the surface-to-skin
distance using electronic brachytherapy. Chen et al.
recently reported a case report of radiation recall asso-
ciated with the eB device and docetaxel administration
[84]. They argued that the prescription of 34 cGy at 1
cm may result in a higher skin dose (when the skin to
balloon distance is less than 1 cm) for eB because of the
relatively higher fall off rate of the 50 KVp photon com-
pared to Ir-192. The patient that they reported had a
surface-to-skin distance of 7.5 mm, greater than the 7
mm MammoSite guideline. The calculated dose to the
skin was approximately 537 cGy per fraction. If an
192Ir
source had been used instead, the skin dose would have
been approximately 470 cGy per fraction, corresponding
t oar e l a t i v ed o s ei n c r e a s ef o rt h ee l e c t r o n i cs o u r c eo f
approximately 14%.
Another potential contributing factor is the increase in
relative biologic effectiveness (RBE, the ratio of doses for
photons of differing energies required to produce the
same biologic effect) related to the lower energy of the
photons emitted by the electronic brachytherapy source.
It is well established that the biological effectiveness of
low-energy photons is large compared with higher-
energy gamma rays, because of the dominance of photo-
electric absorption at low energies [85]. The RBE for a
40 kVp source (very similar to the Axxent photon spec-
trum) has been calculated to be 1.28 greater than. an
192Ir source [85]; hence, the dose from the 192-Ir source
must therefore be 1.28 times greater than that of the
l o we n e r g yp h o t o ns o u r c et op r o d u c et h es a m ee f f e c t
(e.g., skin ulceration).
3. Contura
The balloon catheter of the C o n t u r ad e v i c e( S e n o R x ,
Inc, Aliso Viejo, Ca) differs from the MSB and eB cathe-
ters in that it has multiple lumens for passage of an Ir-
192 HDR source (figure 7). In addition to a central
lumen, the Contura balloon has four surrounding chan-
nels to accommodate the HDR source. The positions of
the surrounding channels have a fixed 5-mm offset
around the central channel [67]. These channels provide
additional source positions and thus allow increased
dose flexibility compared with a single-catheter
approach. This approach has the potential to reduce the
dose to normal tissues (chest wall and skin) and organs
at risk such as the heart and lungs. In addition, multiple
catheters make it possible to account for asymmetric
balloon implant with respect to the central channel.
Like the eB catheter, Contura has a port for a vacuum
to remove fluid or air around the lumpectomy cavity;
the use of this vacuum port can improve tissue-balloon
conformance. The Contura device received FDA clear-
ance in May 2007.
MSB has the longest duration in follow up and new
APBI devices compare its clinical efficacy to that of
MammoSite. A recent study by Wilder et al. [86] evalu-
ated one hundred and eighty-two women with early
breast carcinoma treated with post lumpectomy bra-
chytherapy using Contura (n = 45) and MammoSite
(n = 137) devices with a median follow-up of 16
months. A Contura catheter did not require explanta-
tion in 16% (7 of 45) of patients where balloon-to-skin
spacing was only 3-6 mm and 11% (5 of 45) of patients
where there was an air/fluid pocket greater than 10% of
the planning target volume for plan evaluation. A Mam-
moSite catheter was explanted in 10% of cases where
the minimum balloon-to-skin distance was <7 mm and
in 13% of cases where there was a large air/fluid pocket
next to the balloon. They observed incidence rates of
acute toxicity with a Contura device similar to those
with a MammoSite device [86]. Brown et al. [87] have
also reported similar improvements in dosimetric cap-
abilities (i.e., reduced skin and rib doses and improved
PTV_EVAL coverage) with the Contura device.
Hybrid Brachytherapy Devices
Hybrid devices were developed to take advantages of the
versatility and dosimetric conformity of multicatheter
interstitial brachytherapy with the convenience and aes-
thetics of a single entry device. There are currently two
devices in this category namely the Struts Adjusted
Volume Implant (SAVI) and the ClearPath.
1. Strut Adjusted Volume Implant (SAVI)
The SAVI device (Cianna Medical, Aliso, Viejo, Ca)
(Figure 8) consists of a central strut surrounded by 6, 8
or 10 peripheral struts, depending on the size of the
device [67,88]. The peripheral struts can be differentially
loaded with a HDR source. The device is inserted in col-
lapsed form through a small incision; once placed, it is
then expanded to fit the lumpectomy cavity by clock-
wise rotation of a knurled knob at the proximal end of
the expansion device, expanding the peripheral struts
and providing a pressure fit [89]. The outward pressure
exerted by the expanded struts pushes against the cavity
walls securing the struts in place. Some tissue invagina-
tion between the struts has been observed during the
course of the treatment. Radio-opaque markers are pre-
sent on three of the peripheral struts (number 2, 4 and
6) for identification during the reconstruction process in
treatment planning.
The SAVI device is surgically implanted on an outpati-
ent basis by the treatment radiation oncologist using
ultrasound guidance with the patient under local
anesthesia. A CT scan is acquired immediately following
the implant surgery, both for the verification of the
Njeh et al. Radiation Oncology 2010, 5:90
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ning. It was recommended by Scanderbeg et al [89], that
although the device does not move independently to the
body, one should always try to attain a position as close
to the planned patient position due to breast deforma-
tion. They found a breast board to be best for patient
setup because of its ease of setup and reproducibility.
2. ClearPath (CP)
Another hybrid device similar to the SAVI has also been
developed called ClearPath (CP; North American Scien-
tific (Chatsworth, CA)). CP was developed to combine
the advantage of balloon brachytherapy and multicath-
eter brachytherapy. The CP consists of both inner and
outer catheters that expand by rotating a knob on the
base of the device (Figure 9) [67,90]. The CP device
contains six outer expandable plastic tubes to displace
the tissue. The radii of expansion of these tubes are
adjusted at the base of the device and can be expanded
to conform to a similar shape and size as a balloon
device. In the center of the expandable tubes is a central
catheter surrounded by six additional catheters that
allow the passage of an HDR Iridium-192 source. In
contrast to the SAVI device, the radiation source is not
in direct contact with the breast tissue. In addition, after
the device is placed in the patient, the rubber sleeve is
sutured to the patient, and the base of the device is cut
off. This leaves only the catheters exposed and visible
external to the patient’s skin [91]. Normally a cap is
placed over the HDR channels. This could potentially
lead to increased patient comfort by eliminating the
dangling external catheters.
CP is a relatively new device and hence no clinical out-
come data have been reported. However, retrospective
dosimetric analysis has been reported [90,91]. Dickler
et al. [91] found that MSB and CP offered comparable
target volume coverage, but CP allowed significantly
more normal-tissue sparing. Similarly, Beriwal et al.
simulated a phantom study and the parameters of the CP
catheter were superimposed on the MSB planning CT
scans. The authors found that the median maximum skin
dose was 161% for MSB and 113% for CP of the prescrip-
tion dose [90].
External Beam Radiation Therapy (EBRT)
Several techniques may be classified as ‘external beam
radiation therapy’ including 3D-conformal radiation
therapy (3D-CRT) with multiple static photons, and/or
electrons fields, intensity modulated radiation therapy
(IMRT) and proton beams [92]. The most widely used
3D-CRT approach was initially described by Baglan et al
[93]. This technique was adopted for use as one of the
allowed treatment modalities for patients randomized to
APBI in the National Surgical Adjuvant Breast and
Bowel Project B- 39/Radiation Therapy Oncology group
Figure 7 The Contura balloon applicator (courtesy of SenoRx).
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Page 10 of 28(NSABP/RTOG) 0413 phase III trail [94]. The technique
uses four to five tangentially positioned non-coplanar
beams (Figure 10). The tumor bed is defined by the
computed tomography visualized seroma cavity, post-
operative changes, and surgical clips, when available.
The clinical target volume (CTV) is defined as the
tumor bed with a 1.5 cm margin limited by 0.5 cm from
the skin and chest wall. The planning tumor volume
(PTV) is defined as the CTV with a 1.0 cm margin. The
prescription dose used for NSABP/RTOG protocol is
3.85 Gy twice daily (separated by at least 6 hours) to a
total dose of 38.5 Gy delivered within 1 week [94].
EBRT has many potential advantages, over the other
techniques [95].
1. The technique is non-invasive and the patient is
not subjected to a second invasive surgical procedure
or anesthesia, thereby reducing the potential risk of
complications. The treatment can wait until comple-
tion of pathological analysis about the original
tumor and the status of the resection margins are
available.
2. The technique has potential for widespread avail-
ability since most radiation therapy centers already
perform 3D-CRT for other cancers.
3. It is likely that an external beam approach will be
easier for radiation oncologists to adopt than bra-
chytherapy techniques because the technical
demands and quality assurance issues are much
simpler.
4. Treatment results with external beam may be
more uniform between radiation oncologists because
the outcome depends less on the experience and
operative skills of the person performing the proce-
dure than for brachytherapy (especially using inter-
stitial implantation).
5. It seems less likely that technical issues arising
during external beam radiation therapy will require
the procedure to be aborted as is not infrequently
the case when brachytherapy techniques are used.
6. External beam is intrinsically likely to generate
better dose homogeneity and thus may results in a
better cosmetic outcome when compared with bra-
cytherapy techniques.
Figure 8 Different sizes of SAVI with peripheral struts expanded (courtesy of Cianna Medical).
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and unanswered question remain. These include breath-
ing motion, treatment setups variation, and the fractio-
nation scheme adopted. The target may move during
breathing and the patient may be positioned differently
for different fractions. To avoid missing the planned tar-
get, a large treatment volume is used. A prone patient
position has been suggested by Formenti et al.[96] to
minimize target tissue movement during breathing. The
prone position also provides exceptional sparing of the
heart and lung tissues. Unfortunately, the prone position
is not widely used because it requires a special immobi-
lization device and is uncomfortable for some patients.
The use of multiple treatment fields in 3D-CRT/IMRT
can increase the volume of normal tissue irradiated to
low or moderate doses (i.e increase in integral dose).
Also, 3D-CRT delivers higher doses to normal breast
tissue since the PTV around the lumpectomy cavity is
increased to account to breathing and setup errors [97].
The identification and contouring of the lumpectomy
cavity (LC) is another issue with 3D-CRT APBI. LC
determination is critical because treatment delivery is
Figure 9 ClearPath device (a) the base detached (b) a cap placed over the HDR channels (courtesy of North America Scientific).
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CTV are generally defined as the contouring of a ser-
oma within the lumpectomy cavity, expanded by some
margin, usually 1 cm [93]. However, the delineation of
the seroma could vary among different observers and
even among experienced ones [98]. It has been sug-
gested by Dzhugasvili et al. [99] that the use of surgical
clips as fudicial markers may reduce such observer
variability.
There is still the question of the appropriate dose and
fractional scheme for 3D-CRT APBI. As evident in
Table 3 different doses and fractionation schemes have
been reported in the literature. Rosenstein et al. [100]
assessed the biologically equivalent doses (BEDs) of sev-
eral APBI schedules using a linear quadratic model.
Using an a/b ratio of 10, they found the Vicini fractio-
nation scheme provided a BED of 53 Gy, the Formenti
f r a c t i o n a t i o ns c h e m eg a v e4 8G ya n dt h e3 2 - G yd o s e
used by Taghian et al. [101] gave a BED of 45. Livi et al.
[ 1 0 2 ]i nr a n d o m i z e dP h a s eI I It r i a lh a v eu s e dad o s eo f
30 Gy in five fractions (6 Gy/fraction) and argued that it
was equivalent to 54 Gy in a standard fractionation of 2
Gy fractionation. However, Cuttino et al. [103] utilizing
a wide range of established radiobiological parameters,
determined that the maximum fraction size needed to
deliver a biologically equivalent dose using 3D-CRT is
3.82 Gy, supporting the continued use of 3.85Gy BID in
the current national cooperative trial.
Intra-Operative Radiation Therapy Techniques
Intra-operative radiation therapy (IORT) refers to the
delivery of a single fractional dose of irradiation directly
to the tumor bed during surgery. These techniques have
been reviewed by Reitsamer et al. [112], Vaidya et al.
[113,114] and Orecchia and Veronesi [115]. Older intra-
operative radiation therapy devices were technically
cumbersome, commonly relying on the transportation of
the patient from the operating theatre to the radiation
therapy unit during surgery, or require custom-built
intra-operative radiation therapy theatres [113]. These
technical and financial limitations to delivery of intra-
operative radiation therapy have prevented widespread
use of the approach. Advances in miniaturization tech-
nology have enabled the development of mobile intra-
operative radiation therapy devices. Intra-operative
radiation therapy was first used in 1998 with a device
called the Intrabeam, since then, two other mobile linear
accelerators have become available (the Mobetron and
Novac-7 systems). These systems either generate mega-
voltage electrons (Mobetron and Novac-7) or kilovoltage
photons (intrabeam).
The potential advantages of IORT include delivering of
the radiation before tumor cells have a chance to prolif-
erate. Furthermore, tissues under surgical intervention
have a rich vascularization, with aerobic metabolism,
which makes them more sensitive to the action of the
radiation (oxygen effect). Also, the radiation is delivered
under direct visualization att h et i m eo fs u r g e r y .I O R T
could minimize some potential side effects since skin and
the subcutaneous tissue can be displaced during the
IORT to decrease dose to these structures, and the
spread of irradiation to lung and heart is reduced signifi-
cantly [116]. IORT eliminates the risk of patients not
completing the prescribed course of breast radiotherapy
(a well-recognized risk of conventional breast radiother-
apy) and allows radiotherapy to be given without delaying
administration of chemotherapy or hormonal therapy
[117]. IORT has the potential for accurate dose delivery:
by permitting delivery of the radiation dose directly to
the surgical margins, IORT eliminates the risk of geogra-
phical miss in which the prescribed radiation dose is
inaccurately and incompletely delivered to the tumor
Figure 10 3D-CRT typical 4-field arrangement for right sided lesions and 5 field arrangement for left sided lesions (reprinted with
permission from Baglan et al.[93].
Njeh et al. Radiation Oncology 2010, 5:90
http://www.ro-journal.com/content/5/1/90
Page 13 of 28bed. Geographical miss may result from patient move-
ment, inconsistent patient setup, and difficulty identifying
the tumor site weeks or months postoperatively and is
estimated to occur in up to 70% of patients receiving
conventional breast boost radiotherapy [118]. There is
potential for decreasing healthcare cost because it is one
fraction as opposed to 25 fractions.
With IORT the final pathology reports arrives days
post-festum. This has been one of the major criticisms
of the technique. So recently a novel handheld probe
(Dune Medical Devices, Caesarea, Israel) has been devel-
oped for intra-operative detection of positive margins
[119] Such a device can help reduce re-excision rate and
improve acceptance of IORT technique.
1. INTRABEAM (X-rays)
T h em o b i l eX - r a ys y s t e mI n t r a b e a m ™ is manufactured
by Carl Zeiss (Oberkochen, Germany) [120]. The system
is composed of a miniature, light-weight (1.6 kg) X-ray
source (PRS- 400), combined with a balanced floor
stand with six degrees of freedom to gain access to tar-
get sites throughout the body (Figure 11). The miniature
X - r a ys o u r c eh a sap r o b eo f1 0c ml e n g t ha n d3 . 2m m
diameter. Within this device, electrons are accelerated
to the desired energy level and focused down the probe
to strike a gold target. Various spherical applicators with
a diameter ranging from 1.5 to 5 cm are available to
match the size of the surgical cavity (Figure 12). They
are fixed to the end of the source and placed in the
excision cavity to obtain a homogeneous dose distribu-
tion on the surface of the applicator and consequently
on the surface of the tumor cavity. When mounted onto
the Intrabeam unit, each spherical applicator conforms
the breast tissue around the radiation source to permit
delivery of a uniform field of radiation to a prescribed
tissue depth. Accurate and uniform dose delivery is
further achieved by placement of “pursestring” sutures
within the breast to hold the pliable breast tissue against
the applicator surface [117].
The X-ray system produces low-energy photons (30-
50 KVp) with a steep dose fall-off in soft-tissue; no spe-
cial shielding is therefore required in the room [120].
Dosimetry varies by applicator tip size with the com-
monly used 3.5 cm applicator sphere delivering 20 Gy at
a radius of 1 mm from the surface, 5 Gy at 10 mm and
1G ya t2 7m mi na b o u t2 0m i n u t e s[ 1 1 3 ] .T r e a t m e n t
time lasts for approximately 20 to 45 minutes, depend-
ing on the size of the lumpectomy cavity, the size of the
selected applicator, and the prescribed dose.
Treatment can be carried out in unmodified operating
rooms with minimal exposure to the staff and patient;
rapid dose fall-off in the tissue around the applicator
guarantees minimal exposure of the surrounding tissue
such as the lung and cardiac tissue in the patient.
The physics, radiobiology, dosimetry, and early clinical
applications of this low energy x-ray device have been
fully evaluated, and the device has received Federal
Drug Administration approval for use in any part of the
body since 1999 [121]. The RBE for this low-energy x-
rays have been estimated to be 1.5 [85]. It has been sug-
gested that the biologically weighted dose (physical dose
× RBE) decreases with depth less quickly than physical
dose [85] Therefore despite the steep gradient in physi-
cal dose, an effective uniform biological dose is distribu-
ted inside a rim of about 15 mm around the most often
used intrabeam applicator [122]. Another potential
advantage of Intrabeam is that, because normal tissues
can repair their damaged DNA within a few minutes
but cancer cells with poor DNA- repair machinery may
be unable to repair quickly. So treatment given over a
long time (intrabeam is between 25-35 minutes) may
have a higher therapeutic index than giving similar
doses over 2 to 3 minutes [114].
Table 3 Accelerated partial breast irradiation clinical studies using external beam radiation
Author No of cases Follow up (months) Fractionation scheme IBF Good/Excellent cosmesis
Vicini et al[104] 52 54 3.85 Gy × 10 (bid) 6% n/a
Vicini et al.[105] 91 24 3.85 Gy × 10 (bid) 0% 90%
Chen et al. [106] 94 51 3.85 Gy × 10 (bid) 1.1% 89%
Taghian et al.[107] 99 36 3.2 Gy × 4 (bid)
$ 2% 97%
Formenti et al.[108] 10 36 (minimum) 5.0, 5.5, 6.0 Gy × 5 (10 days) 0% 100%
Formenti et al.[96] 47 18 6.0 Gy x5 (10 days) 0% n/a
Magee et al.[109] 353 96 (mean) 5.0 - 5.31 Gy × 8 (10 days)
& 25% n/a
Leonard et al. [110] 55 34 median 3.85 cGy x10 (bid) 0% n/a
Hepel et al.[94] 60 15 3.85 Gy × 10 (bid) n/a 81.7%
Jagsi et al.[111] 34 > 24 3.85 Gy × 10 n/a 79.5%
$Technique used were: mixed photons and electrons (63 patients), photons alone (16 patients), and protons (20),
&Technique was electron field with a beam
energy of 8-14 MeV, the majority being treated with 10 MeV, IBF = ipsilateral breast failure, n/a = data not available.
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phase III, prospective randomized non-inferiority trial
called TARGIT (targeted intraoperative radiation ther-
apy) began in March 2000. This trial compares single
dose intraoperative radiation therapy targeted to the
tumor bed to conventional whole breast external beam
radiation therapy in early breast cancer.[114,117].
Patients were enrolled from 28 centers in nine countries
including UK, Germany, Italy, USA and Australia. Data
accrual was closed in May 2010 and the results of this
trial have recently been published by Vaidya et al. [123].
In this trial 1113 patients were randomly assigned to the
targeted intraoperative radiotherapy group and 1119
allocated to the whole breast external beam radiation
therapy group. From this, 854 patients received targeted
intraoperative radiotherapy, only 142 received targeted
intraoperative radiotherapy with external beam radio-
therapy and 1025 patients in the external beam radio-
therapy group receiving the allocated treatment. They
observed at 4 years follow up, there were six local recur-
rences in the intraoperative radiotherapy group and five
in the external beam radiotherapy group. The Kaplan-
Meier estimate of local recurrence in the conserved
breast at 4 years was 1.20% (95% CI 0.53-2.71) in the
targeted intraoperative radiotherapy and 0.95% (0.39-
2.31) in the external beam radiotherapy group. The rate
Figure 11 The mobile X-ray intraoperative radiation therapy device: The Intrabeam device intraoperative photon device.
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cally significant. Similarly the total rate of major toxici-
ties was similar in the two groups[123]. This study
presents the first level 1 evidence of the equivalence of
APBI using IORT to WBI and confirms that targeted
I O R Ta l l o w st h ee n t i r ed o s eo fr a d i a t i o nt h e r a p yt ob e
administered in a single fraction at the time of breast-
conserving surgery, thus avoiding the need for repeated
radiation therapy treatments or placement of in dwelling
radiation therapy devices.
Figure 12 Various spherical applicators with diameters ranging from1 . 5t o5c mu s e di nt h ei n t r a b e a md e v i c e( r e p r i n t e dw i t h
permission Holmes et al: [117].
Table 4 Some clinical studies using Intra-operative radiation therapy (IORT)
Author No of cases Median follow up interval(months) Technique IBF Good/Excellent cosmesis
Lemanski et al. [131] 42 30 Electrons 4.8% 100%
Veronesi et al.[130] 590 20 Electrons 0.5% n/a
Mussari et al.[132] 47 48 Electrons 0% 92%
Vaidya et al.[121] 25 24 Photons 0% n/a
Vaidya et al. [123] 854 48 photons 1.2% (95%CI = 0.53-2.71)
$ n/a
$TARGIT phase III trial, at 4 years there 6 local recurrences in the target treated group and 5 in the whole breast treated group, giving the Kaplan-Meier estimates
(not crude estimates), n/a not available, IBF = ipsilateral breast failure.
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The Mobetron (IntraOP Medical Inc, Santa Clara, CA),
is a mobile electron beam intraoperative treatment sys-
tem. The Mobetron system (Figure 13a) is composed of
three separate units: the control console, the modulator
and the therapy module [124]. The control console
which operates the accelerator during radiation treat-
ment delivery is placed outside the OR so that the radia-
tion treatment delivery is controlled remotely. The
modulator houses the electronic systems of the accelera-
tor and energizes the accelerator to produce the elec-
tron. The therapy module houses the accelerator guide
and control systems that generate and deliver radiation
[125]. The Mobetron uses two X-band (3 cm wave-
length, 10 GHz frequency) collinear accelerators. This
design eliminates the need for a bending magnet thus
affecting a reduction in photon leakage [126]. The
Mobetron system produces electrons of nominal ener-
gies of 4 MeV, 6 MeV, 9 MeV and 12 MeV with thera-
peutic ranges up to 4 cm. The system is designed to
d e l i v e rav e r yl a r g eu n i f o r md o s eo f1 0t o2 5G yi na
single fraction at a dose rate of 10 Gy/min [124].
3. NOVAC-7 (electrons)
The NOVAC-7 system (Figure 13b) (Hitesys, Latina,
Italy) delivers electrons with the use of a mobile dedi-
cated linear accelerator; its radiating head can be moved
by an articulated arm that can work in an existing oper-
ating room. It is based on a compact S-band standing
wave electron beam linear accelerator utilizing a
patented auto-focusing structure which eliminates the
need of focusing solenoids. The accelerator is moved by
six axis robotic arm. It delivers electron beams at four
different nominal energies (3, 5, 7 and 9 Mev) [113].
Beam are collimated by means of a hard docking sys-
tem, consisting of cylindrical perspex applicators avail-
able in different diameters (4 to 10 cm) and angles of
the head (perpendicular or oblique 15° to 45° with
respect to their axis).
A phase III, prospective randomized trial called
ELIOT (electron intraoperative therapy) began in 2000
in Italy. A single dose of 21 Gy with energies up to 9
MeV, biologically equivalent to 58-60 Gy in standard
fractionation is applied to the tumor bed. The dose of
21 Gy was established from a dose-escalating phaseI/II
Figure 13 The mobile electron intraoperative radiation therapy devices: (a) Novac7 (b) Mobetron intra-operative electron device
(reprinted with permission Beddar el al. [124]).
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from the depth of the tissue to be irradiated. The accel-
erators used have been designed to have a dose rate
(15-20 Gy per minute) higher than conventional and
can deliver 21 Gy in less than 2 min [115]. The entire
procedure last for about 15 to 20 minutes. Unnecessary
radiation to the underlying normal tissue can be avoided
by mobilizing the mammary gland during surgery and
placing a lead plate for shielding on its dorsal surface.
The costs of the mobile linear accelerator with a
robotic arm, used in intra-operative radiation therapy,
are prohibitive for poor countries. Frasson et al. [128]
evaluated the feasibility of ELIOT in the accelerator
room of the radiation therapy service for early breast
cancer treatment; demonstrating that intra-operative
radiation therapy with electrons can be safely performed
in an accelerator room with a conventional machine.
A systematic review by Cuncins-Hearn et al. [129]
concluded that the short-term results were similar for
both BCT and IORT in terms of local recurrence, dis-
ease-free and overall survival. The current evidence base
is however poor, making definitive assessment on IORT
very difficult. They suggested that further research is
required to clarify several issues such as identification of
the most appropriate subgroups of patients for IORT, a
comparison of the currently available mobile IORT tech-
nologies, establishing whether IORT is most appropriate
as a boost replacement dose or replacement for all post-
operative radiation therapy, the examination of how bio-
logical repair processes may differ between the two
treatment modalities and determining precisely where
local recurrences originate with respect to the original
tumor site.
The IORT approach has the advantage of shortening
the treatment course further, conveniently delivering the
entire course of local therapy at the time of initial exci-
sion. However, IORT also presents significant technical
challenges, not the least due to the need for accuracy of
target definition and treatment delivery inherent in a
single dose radiotherapy delivery. One issue is the accu-
racy of tumor bed definition when tissues are re-
approximated following excision. Another is the variable
margin of normal tissue irradiated in the re-opposed tis-
sues. IORT may be complicated in patients who are
determined to have positive surgical margins and need
re-excision. This may not have been a significant issue
in the Versonesi studies [130], as all patients received
generous resections with quadrantectomies.
Discussion
The issue of the need and utility of APBI is highly
debated within the medical community. There are those
of the school of thought that the current standard of
care for early breast cancer works well. So, the frame of
mind is “if it is not broken why fix it?”,e v i d e n c e db y
the commentary in medical journals such as “Is APBI a
step backward?” [133]. On the other hand, there are
those who belief that APBI has a role to play in the clin-
ical management of early stage breast cancer [134]. If
the proliferation of APBI techniques is anything to go
by, there is indeed a high level of interest. As reviewed
in this paper, there are several different approaches to
APBI, each with their merits and limitations (Table 5,
[135]). For those who believe in the role of APBI, there
is a general consensus that a few questions remain to be
satisfactorily addressed including the appropriate fractio-
nation scheme, the appropriate patient selection criteria,
the need for phase II/III clinical trials establishing
equivalence or improvement to WBI and the appropri-
ate technique.
Patient Selection
Patient selection is critical to the successful application
of APBI[136]. In a recent review, Polgar et al. [137]
argued that the relatively poorer results of early APBI
studies, with high local recurrence rates exceeding 1%
per year could be attributed to inadequate patient selec-
tion criteria and/or suboptimal treatment technique and
lack of appropriate QA procedures. Similarly in a recent
s t u d yb yC h e ne ta l .[ 7 6 ] ,7 0p a t i e n t sw e r et r e a t e dw i t h
MammoSite at the median follow up of 26.1 months,
four local failures were observed of which two did not
meet the ABS and ASBS selection criteria. These failures
highlight the need to better define the subset of patients
f o rw h o mA P B Ii sm o s ta p p r o p r iate. Various societies
have now published recommendations of patient selec-
tion criteria for APBI. These include, the American
Society of Breast surgeons (ASBS), the American Bra-
chytherapy Society (ABS), American Society for Radia-
tion Oncology (ASTRO) and European Society for
therapeutic Radiology and Oncology (ESTRO)
[48,137,138]. The recent GEC-ESTRO recommendations
([137] have stratified the patients into three groups: low
risk, intermediate and high risk (contraindication for
APBI); similarly, ASTRO [138] has stratified them into
suitable, cautionary and unsuitable. The low risk (suita-
ble) group describes patients where APBI outside of a
clinical trial would be considered acceptable (see Table
6); these criteria are stricter than those recommended
by the ASBS or ABS. However, less restrictive criteria
could be applied to patients who enrolled in a clinical
trial. Generally young patients (< 50 years) and those
who may harbor disease a significant distance from the
edge of the excision cavity or potentially have multi-cen-
tric disease should not be treated with APBI off proto-
col. It also worth noting that these recommendations
were determined from a systematic review of the APBI
literature. The groupings were based primarily on an
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Page 19 of 28analysis of the characteristics of patients most frequently
included in trials of APBI and not on data that identi-
fied subsets of patients with higher rates of ipsilateral
breast tumor recurrence (IBTR) when treated with
APBI. Recent analysis using ASBS registry trial [139,140]
and using data from using of University of Wisconsin
[141] show that the ASTRO consensus groupings may
not be optimal in identifying patients for APBI.
Fractionation Scheme
One concern regarding APBI is the proliferation of
approaches; this inherently makes it difficult to elucidate
the generic effect of APBI from the specific effect of a
particular technique. As described within this review,
many dosing schemes have been used; the different frac-
tionation schemes and different BED make it possible
for a failure to occur due to inappropriate dosing rather
than the fact that only a partial region of the breast had
been irradiated using APBI. Taking the 3D-CRT
approach as an example, (see Table 3) many dosing
schemes have been reported; for example, in the ELIOT
studies, three different dose levels were used: 20 Gy
(seven patients), 22 Gy (20 patients), and 24 Gy (20
patients) [132]. Further, the use of soft x-rays as in
Intrabeam and Xoft approaches introduce another con-
cept of relative biological effectiveness; thereby introdu-
cing another variable when trying to determine the
effectiveness of the dosing.
Target Definition
The basic tenet of radiation therapy is the delivery of a
tumorcidal dose to the clinical target volume. In terms
of applying APBI, there are questions of the appropriate
target volume; is 1 cm or 2 cm enough margin for the
irradiation of residual tumor? Depending on the particu-
lar technique, the delineation of this target can be pro-
blematic. It has been well documented that
inappropriate target delineation will result in under dos-
ing of the tumor or irradiating excessive volumes of
normal tissues and organ at risk [142]. For non-bra-
chytherapy techniques, substantial differences in delinea-
tion of the lumpectomy cavity have been observed, even
by dedicated breast radiation oncologists [98]. The defi-
nition of the CTV is influenced by clinical features in
the breast such as dense breast parenchyma, benign cal-
cifications, low seroma clarity score, small volume and
proximity to the pectoralis muscles [143]. To facilitate
the contouring, surgically placed clips after lumpectomy
have demonstrated strong radiographic surrogates of the
lumpectomy cavity [99,144]. Also, written guidelines for
contouring CTV have been shown to significantly
reduce the inter-observer variability and minimize the
volumes for radiation [145].
Clinical Trial Evidence
As seen in tables 1, 2, 3, 4, the longest follow-up for
APBI is with multi-catheter interstitial brachytherapy
Table 6 ASTRO and GEC-ESTRO suitable patient recommendation selections for APBI outside of clinical trials
Suitable group by ASTRO [138] Low Risk group by GEC-ESTRO [137]
Factors Criterion Criterion
Age > 60 y > 50
BRCA 1, 2 Mutation Not present na
Tumor Size < 2 cm < 3 cm
T stage T1 T1-2
Margins Negative by at least 2 mm Negative by at least 2 mm
Grade any any
LVSI Not allowed Not allowed
ER status positive any
Multicentricity unicentric unicentric
Multifocality Unifocal with total size of < 2 cm unifocal
Histology IDC, mucinous, tubular and colloid IDC, mucinous, medullary, colloid
DCIS Not allowed Not allowed
EIC Not allowed Not allowed
Associated LCIS Allowed Allowed
Nodal status pN0 (by SN Bx or ALND pN0 (by SLNB or ALND)
Neoadjuvant Therapy Not allowed Not allowed
APBI = accelerated partial breast irradiation, IDC = invasive ductal carcinoma, ILC = invasive lobular carcinoma, LCIS = lobular carcinoma in situ; DCIS = ductal
carcinoma in situ; EIC = extensive intraductal component; LVI = lympho-vascular invasion; ER = estrogen receptor; SLNB = sentinel lymph node biopsy; ALND =
axillary lymph node dissection
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rates of 3.6% at 10 years. More recently, Polgar et al.
[58] reported a 12 year prospective study using MIB;
four (8.9%) ipsilateral breast tumor recurrences were
observed, for a 5-, 10- and 12 year actuarial rate of
4.4%, 9.3% and 9.3% respectively. The other techniques
have shorter follow-up, with no local recurrence rates at
5 years follow up for MammoSite brachytherapy (MSB)
[73], no reported recurrences in 10 to 28 months with
single institution studies of 3D-CRT and 1.3% at 19
months in a single-institution study of intra-operative
radiation therapy (IORT) [147].
It is now accepted that critical evaluation of clinical
studies is appropriately done in terms of evidence based
medicine. There are a few methodologies for reviewing
the quality of the evidence including SORT (strength of
recommendation taxonomy)[148], Grade (grades of
recommendation, assessment, development and evalua-
tion)[149] and CEBM (center for evidence based medi-
cine). This critical evaluation is usually done under the
umbrella of a systematic review and meta-analyses. The
present review was not designed as a systematic review,
but as a detailed analysis focussed towards providing the
details and nuances of the different techniques. None-
theless, an evaluation of a particular technique will not
be complete without some assessment of its clinical
validity. In terms of the SORT approach of clinical evi-
dence, RCT provides level 1 clinical evidence of efficacy
and validity. There are currently four reported APBI
RCT [63,123,150,151]. However, not all of these studies
met the SORT recommendation of quality, quantity and
consistency. The YBCG (Yorkshire Breast Cancer
Group)[151] and Christie Hospital[150] trials lack con-
sistency in terms of patient selection and appropriate
target definition, So, these two trials only provides level
3 evidence of efficacy. The Hungary trial [63] lacks the
sample size to detect a difference. Hence, the only RCT
that provides level 1 evidence is the recently published
TARGIT study[123]. Case control studies provide level
3 evidence of efficacy and validity. Hence, for the other
APBI techniques (MIB, Mammosite, 3DCT, and electron
IORT) there is currently only level 3 evidence of
efficacy.
Hence clinical community awaits the results of the
other ongoing trials for more data on the long-term
effectiveness of these techniques. Seven current phase
III randomized clinical trials are currently evaluating the
clinical efficacy of these APBI techniques (see Table 7);
these studies include the National Surgical Adjuvant
Breast and Bowel Project (NSABP) B- 39/Radiation ther-
apy oncology group (RTOG) 0413 trial, RAPID(rando-
mized trial of accelerated partial breast irradiation)/
Ontario clinical oncology group, GEC-ESTRO,
IMPORT-LOW (intensity modulated and partial organ
radiotherapy) trial in the UK, electron intra-operative
therapy (ELIOT) trial and targeted intra-operative radio-
therapy (TARGIT) [52]. These trials have been exam-
ined in great details recently by Mannino and Yarnold
[27] identifying the differences between them. These
trials differ in patient selection criteria, radiotherapy
technique used in the experimental (APBI) arm, radia-
tion dose and fractionation scheme [27,152]. The sample
size also varies with the different trials. If one was to
assume an annual recurrence rate of 1% or less and a
randomization ratio of 1:1, one will need about 810
patients per arm, assuming no attrition in three years
(80% power and 95% confidence). All the trials met this
requirement apart from the ELIOT trial. A larger sam-
ple size as required in the NSABP trial increases the
power to detect smaller differences. In addition, a larger
sample size makes it possible to study subgroups of
patients with statistical power to detect a difference. If
these trials accrue to target, almost 16000 women will
be followed, hence providing level I evidence for or
against the application of APBI in women with early
stage breast cancer.
APBI in Asia
Breast Conservation Therapy (BCT) in the Asia region
has not observed the level of interest and growth
observed in the western countries. In Hong Kong, the
limited usage of BCT has been associated with limited
number of radiation therapy facilities [154]. However,
because of the increasing local experience in the admin-
istration of BCT, increasing numbers of young patients
in the population and increasing efforts to promote
breast cancer awareness in recent years, the use of BCT
is steadily increasing [154]. For example, in Western
Australia the proportion of women under going initial
BCT doubled from 33% in 1982-1985 to 72% in 1998-
2000 [155]. One will further expect that APBI to
increase the use of BCT in the management of early
breast cancer. However, there is another issue in the
application of APBI to the Asian population which is
breast size. Asian women generally have smaller breast
compare to European. Some of the APBI techniques
might be challenging to apply to this patient group. In
Japan for example, excision involving 2 cm free margin
from the tumor is most commonly performed. In many
cases mammary gland tissue does not remain on the
dermal or pectoralis muscle sides of the tumor. The tar-
get of irradiation is only the lateral stump [23]. Hence
APBI techniques like the Mammosite will not be very
applicable in the Asian population, because of potential
excessive radiation dose to the skin. Maybe more con-
formal techniques like the SAVI or Clearpath might be
appropriate. However, treatment results have not yet
been published.
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region. When irradiation is performed in the supine
position, flat extension of the breast reduces the dis-
tance between the target of the irradiation and the skin,
leading to excessive exposure of the skin. However,
using the 4field technique of 3D-CRT, Kosata et al.
[ 1 5 6 ]d e m o n s t r a t e dt h a ti nJ a p a n e s ew o m e n ,p a t i e n t s
with a laterally located small tumor can be candidates
for APBI, although patients with medially located tumor
cannot. They also noted that a new beam arrangement
using a combination of photons and electrons (a three-
field technique that consisted of opposed, conformal
tangential photons and enface electrons) recently pro-
posed by Massachusetts General Hospital [101] may be
more suited to Japanese women than that of the NSABP
B-39/RTOG 0413 protocol [156].
IORT is also been explored as a way to provide APBI
to the Japanese population. A phase I study designed
using a scheme of dose-escalation from 19, 20, and 21
Gy at 90% isodose has been reported by Sawaki et al.
[157]. The IORT treatment was well tolerated in Japa-
nese women, with a prescription dose of 21 Gy was
recommended.
Dose Coverage
The coverage of the target varies depending on the tech-
nique. There are limited studies evaluating multiple
techniques [158]. Weed and colleagues compared 3D-
CRT, mammosite and interstitial brachytherapy; they
found that at the coverage at 90% of the prescribed
dose, no difference was observed between 3D-CRT and
MammoSite (which were both better than interstitial)
[158]. 3D-CRT resulted in better coverage of the PTV
compared with MammoSite or interstitial brachytherapy
techniques. Better PTV coverage with 3D-CRT came at
the cost of a higher integral dose to the remaining
Table 7 Prospective randomized phase II clinical APBI adapted from Offersen et al. [52] and Lehman and Hickey [152]
WBI = whole breast irradiation, RAPID = randomized trial of accelerated partial breast irradiation
Trial Trial Design N Inclusion Control Arm APBI technique (Experimental
Arm)
Status
TARGIT
[123]
Equivalence 2232 ≥ 45 years
T1 small T2, N0, 1, Ductal
WBI as per institutional
guidelines
IORT, Low energy X-rays 50 KV,
20 Gy/1 fraction
Started March 2000,
completed
enrollment march
2010
ELIOT
[115]
Equivalence 824 ≥ 48 years
invasive carcinoma
T ≤ 2.5 cm, pN0,
Quadrantectomy
WBI, 50 Gy/25 fractions +
optional 10 Gy Boost
IORT 21 Gy/1 fraction, electrons
up to 9 MeV
Started in Dec 2000
GEC-
ESTRO
Non-inferiority,
non-irrelevant,
3% difference
1170 ≥ 40 years
stages O-II ductal/lobular
carcinoma
T ≤ 3 cm, pNO-pNmi,
margin ≥ 2m m
WBI 50- 50.4 Gy/25-28
fractions + optional 10 Gy
boost
MIB, 32 Gy/8 fractions HDR, 30.3
Gy/7 fractions HDR, 50 Gy PDR
Started 2004
NSABP/
RTOG
0413
Equivalence 4300 ≥ 18 years
stage 0, I, II (T < 3 cm)
DCIS or invasive
adenocarcinoma, ≤ 3 nodes
positive, Margin negative
WBI
50-50.4 Gy/25-28 fractions,
optional 10- 16 Gy boost
MIB
Mammosite 34 Gy/10 fractions
(5-10 days)
3D EBCRT 38.5 Gy/10 fractions
(5-10 days)
Started in 2005
(accrual now closed
to low risk patients)
RAPID Equivalence 2128 ≥ 40 years
DCIS or invasive carcinoma
T< 3 cm, margin negative,
node negative, not BRCA 1/
BRCA 2
WBI 42.5 Gy/16 fractions/22
days (small breast)
50 Gy/25 fractions/35 days
(large breast plus optional
boost 10 Gy/4-5 fractions
3D CRT 38.5 Gy/10 fractions (5-8
days)
Minimum daily fraction
separation 6 -8 hours
Started in January
2006
IMPORT-
LOW
Non-inferiority 1935 ≥ 50 years
invasive adenocarcinoma
(not lobular) T ≤ 3 cm,
margin ≥ 2 mm, node
negative
WBI
40 Gy/15 fractions/21 days
EBRT (IMRT)
Arm 1 40 Gy/15 fractions to
primary tumour region + 36 Gy/
15 fractions to low risk region
Arm 2 40 Gy/15 fractions to
primary tumour region
Started in 2006
IRMA Non-inferiority n/a ≥ 49 years
pT1-2 (< 3 cm)
invasive carcinoma
pN0- N1
Margins ≥ 2m m
WBI
45 Gy/18 fractions, or 50
Gy/25 fractions, or 50,4 Gy/
28
fractions
3D CRT
38.5 Gy total in 10 fractions
(3.85 Gy per fraction), twice a
day
with an interval of at least 6
hours
Started in 2007
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irradiation technique appears to depend on the clinical
situation.
Quality of Life (QOL)
In addition to local control, improved survival and bet-
ter cosmesis, quality of life is also an important variable
in evaluating treatment technique for breast cancer
patients; with limited studies evaluating QOL aspects of
breast cancer treatment. In a study by Wadasadawala et
al [159], comparing APBI and WBI they found that the
scores for social functioning and financial difficulties
showed a trend towards a better outcome in the APBI
group (p = 0.025 and p = 0.019 respectively). However,
body image was significantly better in the APBI group
as compared with the WBRT group (p = 0.005). Reports
evaluating QOL for the different APBI have not been
reported to date; although patients undergoing Mammo-
site have been reported to be very satisfied with their
outcome [160].
Cost Effectiveness
In the age of rapidly increasing health care costs, eva-
luation of techniques has to include cost effectiveness.
Cost comparisons have been reported by Suh et al.
[161,162] and Sher et al. [163] modeled treatment plan-
ning and delivery for different WBI fractionation
schemes, Mammosite, MIB,A P B I-3 D C R Ta n dA P B I -
IMRT. They found that the least expensive partial
breast-based radiation therapy approaches were the
external beam techniques (APBI-3D-CRT and APBI-
IMRT); any reduced cost to patients for the HDR bra-
chytherapy-based APBI regimens were overshadowed by
substantial increases in cost to payers, resulting in
higher total societal costs. The cost of HDR treatment
delivery was primarily responsible for the increased
direct medical cost. APBI approaches in general were
favored over whole-breast techniques when only consid-
ering costs to patients. However, If one were to pursue
a partial-breast radiation therapy regimen to minimize
patient costs, it would be more advantageous from a
societal perspective to pursue external beam-based
approaches such as APBI-3D-CRT or APBI-IMRT in
lieu of the brachytherapy-based regimens [162]. Simi-
larly, Sher et al. [163] reported that APBI-3DCRT was
the most cost-effective strategy for postmenopausal
women with early-stage breast cancer. Unless the qual-
ity of life after MSB proves to be superior, it is unlikely
to be cost-effective [163].
Further Research
As eluded in this review, there are still a few unan-
swered questions including optimal technique, patient
selection and target volume definition.
1 Optimal Technique
As reviewed herein, there are quite a variety of techni-
ques available for APBI, but with insufficient clinical
and dosimetric data to determine the optimal technique.
It is worth noting that none of the current RCT will
address this issue since a direct comparison of the tech-
nique is not part of any of the current trials. So research
is required to determine (a) what is the optimal techni-
que? (b) what technique is best for which patient? Breast
size and location of the lumpectomy cavity might dictate
which technique to use. For example, small breasted
patients might be best suited for IORT, while larger
breasted are best served by balloon based brachytherapy
techniques such as the MammoSite.
2 Patient Selection
T h e r ei sy e tt ob eac o n s e n s u si nt e r m so fw h i c h
patients characteristics are suitable for APBI. Different
societies have come up with varying patient selection
criteria. Current data analysis shows that these recom-
mendations might not be optimal. Therefore there is a
need for a definitive clinical and pathological criteria for
APBI patient selection.
3. Target Volume Definition
As reviewed herein, the volume of breast tissue irra-
diated varies with the technique used. Empirical and
pathological studies are required to determine the level
and degree of spread of micro-calcification. This will
give a definitive guidance on how much tissue needs to
be irradiated.
4 Optimal Dose and Fractionation Scheme
There is growing evidence that the linear quadratic
model (LQM) may not be appropriate for modeling
high dose per treatment[164,165]. It has been suggested
that LQM consistently overestimates cell killing at high
single doses because it predicts a survival curve that
continuously bends downward, whereas the experimen-
tal data are consistent with a constant slope (D0) at
high doses. Furthermore, high-dose radiotherapy is
achieving higher local control than could be explained
by our current knowledge of radiation killing of cancer
cells in a tumor. Proper radiobiological modeling is
required to determine the optimal dose for APBI and
fractionation scheme for the different techniques. The
impact of the radiation energy used in determining the
dosing also has to be investigated. For example,
the dose for low energy x-rays will be different from the
dose needed for high energy x-rays.
5. Imaging and Pathology
The role of imaging in the management of most diseases
is unquestionable. This is also true for breast cancer
management. The success of APBI depends highly on
the ability to identify patients at low risk of multi-cen-
tric disease. Hence, the appropriate imaging technique
has to be determined. For example, the value of adding
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phy remains controversial[166]. Hence, an imaging tech-
nique is required to increase the specificity and
sensitivity of multi-centric disease diagnosis.
Conclusions
The interest in APBI is evident from the proliferation of
approaches and devices. However, studies are required,
not only to evaluate the efficacy of APBI, but also to
assess the safety and toxicity of the various techniques
and dosing schedules. Furthermore, it is hoped that
more research will be carried out to determine the
strengths and weaknesses of the different techniques;
thereby creating a consensus and identifying where each
technique may be best applied. Whole Breast Irradiation
(WBI) as part of Breast Conservation Therapy has well
established results in terms of disease control, good
cosmesis, and low toxicity. The acceptance of APBI as a
standard of care therefore rides on its ability to match
or better WBI in terms of efficacy, quality of life out-
comes, and cost-effectiveness.
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